Cargando…

Efficacy and safety of different doses of baricitinib for rheumatoid arthritis: A Bayesian network meta-analysis

To evaluate the comparative efficacy and safety of baricitinib with different dosages in patients with rheumatoid arthritis (RA). METHODS: PubMed, Embase, and the Cochrane Library were retrieved by computer to gather randomized controlled trials (RCTs) of baricitinib for RA from their beginning to S...

Descripción completa

Detalles Bibliográficos
Autores principales:	Haikun, Wang, Na, Wu, Dan, Su
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9509125/ https://www.ncbi.nlm.nih.gov/pubmed/36197174 http://dx.doi.org/10.1097/MD.0000000000030676

Ejemplares similares

Safety and efficacy of baricitinib in elderly patients with rheumatoid arthritis
por: Fleischmann, Roy, et al.
Publicado: (2017)

Cardiovascular Safety During Treatment With Baricitinib in Rheumatoid Arthritis
por: Taylor, Peter C., et al.
Publicado: (2019)

Baricitinib for the treatment of rheumatoid arthritis
por: Urits, Ivan, et al.
Publicado: (2020)

Comparative Efficacy and Safety of Peficitinib Versus Tofacitinib and Baricitinib for Treatment of Rheumatoid Arthritis: A Systematic Review and Network Meta-Analysis
por: Tanaka, Yoshiya, et al.
Publicado: (2021)

Janus Kinase Inhibitors in Rheumatoid Arthritis: An Update on the Efficacy and Safety of Tofacitinib, Baricitinib and Upadacitinib
por: Harrington, Robert, et al.
Publicado: (2023)

Are There Any Ethnic Differences in the Response to Baricitinib for the Treatment of Rheumatoid Arthritis?
por: Zahir Hussain, Wajith Hussain, et al.
Publicado: (2021)

Baricitinib exposure during pregnancy in rheumatoid arthritis
por: Costanzo, Giulia, et al.
Publicado: (2020)

Real-world comparative effectiveness and safety of tofacitinib and baricitinib in patients with rheumatoid arthritis
por: Iwamoto, Naoki, et al.
Publicado: (2021)

Efficacy and Safety of Baricitinib in Chinese Rheumatoid Arthritis Patients and the Subgroup Analyses: Results from Study RA-BALANCE
por: Yang, Yue, et al.
Publicado: (2020)

Comparative efficacy, safety and cost of oral Chinese patent medicines for rheumatoid arthritis: a Bayesian network meta-analysis
por: Zhang, Dan, et al.
Publicado: (2020)

Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate
por: Keystone, Edward C, et al.
Publicado: (2015)

New alternative in the treatment of rheumatoid arthritis: clinical utility of baricitinib
por: Kawalec, Paweł, et al.
Publicado: (2019)

A JAK Inhibitor for Treatment of Rheumatoid Arthritis: The Baricitinib Experience
por: Taylor, Peter C., et al.
Publicado: (2023)

Dose/Exposure‐Response Modeling to Support Dosing Recommendation for Phase III Development of Baricitinib in Patients with Rheumatoid Arthritis
por: Zhang, Xin, et al.
Publicado: (2017)

Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritis
por: Harigai, Masayoshi, et al.
Publicado: (2020)

A Network Meta-Analysis to Compare Effectiveness of Baricitinib and Other Treatments in Rheumatoid Arthritis Patients with Inadequate Response to Methotrexate
por: Fakhouri, Walid, et al.
Publicado: (2020)

Palmoplantar Pustulosis-like Eruption Induced by Baricitinib for Treatment of Rheumatoid Arthritis
por: Koumaki, Dimitra, et al.
Publicado: (2019)

Efficacy and safety data based on historical or pre-existing conditions at baseline for patients with active rheumatoid arthritis who were treated with baricitinib
por: Combe, Bernard, et al.
Publicado: (2019)

Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: results of a prospective study
por: Takeuchi, Tsutomu, et al.
Publicado: (2019)

Response to baricitinib based on prior biologic use in patients with refractory rheumatoid arthritis
por: Genovese, Mark C, et al.
Publicado: (2018)

Effectiveness of Baricitinib in Refractory Seronegative Rheumatoid Arthritis and Uveitis: A Case Report
por: Kaneko, Yutaka, et al.
Publicado: (2022)

Systematic Literature Review of Real-World Evidence on Baricitinib for the Treatment of Rheumatoid Arthritis
por: Hernández-Cruz, Blanca, et al.
Publicado: (2023)

Difficult-to-treat rheumatoid arthritis treated with Abatacept combined with Baricitinib: A case report
por: Qi, Jia-Ping, et al.
Publicado: (2023)

Efficacy and safety of baricitinib for active rheumatoid arthritis in patients with an inadequate response to conventional synthetic or biological disease-modifying anti-rheumatic drugs: A meta-analysis of randomized controlled trials
por: Wu, Zhi-Peng, et al.
Publicado: (2018)

Efficacy and safety of secukinumab in patients with psoriatic arthritis: A meta-analysis of different dosing regimens
por: Zhang, Kai-Lin, et al.
Publicado: (2021)

Efficacy and safety of baricitinib in patients with refractory alopecia areata
por: Wang, Yuqian, et al.
Publicado: (2022)

Safety and Effectiveness of Baricitinib in Chinese Patients with Moderate-to-Severe Rheumatoid Arthritis: 24-Week Results from a Post-Marketing Safety Study
por: Wu, Chan-yuan, et al.
Publicado: (2023)

Efficacy and safety of tofacitinib versus baricitinib in patients with rheumatoid arthritis in real clinical practice: analyses with propensity score-based inverse probability of treatment weighting
por: Miyazaki, Yusuke, et al.
Publicado: (2021)

Comparative efficacy and safety of abrocitinib, baricitinib, and upadacitinib for moderate‐to‐severe atopic dermatitis: A network meta‐analysis
por: Wan, Huiying, et al.
Publicado: (2022)

Characterization and Changes of Lymphocyte Subsets in Baricitinib‐Treated Patients With Rheumatoid Arthritis: An Integrated Analysis
por: Tanaka, Yoshiya, et al.
Publicado: (2018)

Temporary interruption of baricitinib: characterization of interruptions and effect on clinical outcomes in patients with rheumatoid arthritis
por: Emery, Paul, et al.
Publicado: (2020)

Baricitinib therapy response in rheumatoid arthritis patients associates to STAT1 phosphorylation in monocytes
por: Tucci, Gloria, et al.
Publicado: (2022)

Comparison of the efficacy and safety indicators of DMARDs for rheumatoid arthritis: A network meta-analysis
por: Wang, Zunlian, et al.
Publicado: (2021)

Baricitinib induces LDL-C and HDL-C increases in rheumatoid arthritis: a meta-analysis of randomized controlled trials
por: Qiu, Chengfeng, et al.
Publicado: (2019)

Efficacy and safety of baricitinib in patients with alopecia areata: evidence to date
por: Faria, Sofia, et al.
Publicado: (2023)

Efficacy of baricitinib in patients with moderate-to-severe rheumatoid arthritis with 3 years of treatment: results from a long-term study
por: Smolen, Josef S, et al.
Publicado: (2020)

Correction to: Temporary interruption of baricitinib: characterization of interruptions and effect on clinical outcomes in patients with rheumatoid arthritis
por: Emery, Paul, et al.
Publicado: (2020)

Cost-effectiveness analysis of baricitinib versus adalimumab for the treatment of moderate-to-severe rheumatoid arthritis in Spain
por: Schlueter, Max, et al.
Publicado: (2019)

Baricitinib inhibits structural joint damage progression in patients with rheumatoid arthritis—a comprehensive review
por: Emery, Paul, et al.
Publicado: (2021)

Cost-Effectiveness of Baricitinib for Patients with Moderate-to-Severe Rheumatoid Arthritis After Methotrexate Failed in China
por: Li, SiNi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_g48adp4hu05ot40cg21dfnaa6j